JILIN AODONG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.08 CNY | +2.65% |
|
+2.17% | -0.40% |
| 04-17 | Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20% | MT |
| 04-16 | Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 4.12B 569M 777M | Sales 2025 * | 4.83B 667M 911M | Capitalization | 18.03B 2.49B 3.4B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.33B 321M 439M | Net income 2025 * | 2.69B 372M 508M | EV / Sales 2024 * | 4.38 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.73 x |
| P/E ratio 2024 * |
7.52
x | P/E ratio 2025 * |
6.51
x | Employees | 5,646 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.05% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.65% | ||
| 1 week | +2.17% | ||
| Current month | +4.29% | ||
| 1 month | +5.23% | ||
| 3 months | +2.10% | ||
| 6 months | -8.55% | ||
| Current year | -0.40% |
1 week
14.61
15.11
1 month
14.0715.11
Current year
13.1315.66
1 year
13.1318.17
3 years
13.1319.90
5 years
13.1319.90
10 years
11.4535.62
| Managers | Title | Age | Since |
|---|---|---|---|
Shu Qin Guo
CEO | Chief Executive Officer | 61 | 97-12-31 |
Kai Yang
DFI | Director of Finance/CFO | 47 | 04-04-30 |
Da Long Zhao
DFI | Director of Finance/CFO | 50 | 99-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiu Lin Li
CHM | Chairman | 71 | 93-01-31 |
Shu Qin Guo
CEO | Chief Executive Officer | 61 | 97-12-31 |
Yu Ju Sun
BRD | Director/Board Member | 52 | 08-05-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 15.08 | +2.65% | 23,697,950 |
| 24-04-25 | 14.69 | -0.61% | 8,121,685 |
| 24-04-24 | 14.78 | +0.14% | 8,104,715 |
| 24-04-23 | 14.76 | +0.48% | 9,348,471 |
| 24-04-22 | 14.69 | -0.47% | 9,672,024 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows:
- sale of pharmaceutical products (89.4%);
- sale of food products (6.8%);
- other (3.8%).
All sales are in China.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.08
CNY
Average target price
22.67
CNY
Spread / Average Target
+50.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.40% | 2.49B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 000623 Stock
